Evaluate the Pharmacokinetics and Gonadotropin Suppression of Nestorone®-Testosterone (NES/T) Combination Gel in Men

Phase 1 Completed 44 enrolled Kimberly Myer Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collab

RandomizedParallel-groupTriple-blindOther

Summary

This is a prospective, randomized, double-blinded, two-center trial to evaluate the gonadotropin suppressive activity of transdermal treatment with a combined NES/T gel, or T gel alone, for 28 days.

Timeline

Start: 2015-04
Primary completion: 2016-03
Completion: 2016-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Segesterone Acetate	Small molecule	8.3 mg	Topical
Subject	Testosterone	Small molecule	62.5 mg	Topical
Subject	Testosterone	Small molecule	62.7 mg	Topical

Indications

No indication recorded.